NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize ...

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...